RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Responsiveness and minimally important difference of sf-6d and eq-5d utility scores for the treatment of pelvic organ prolapse
Harvie, H. S., Honeycutt, A. A., Neuwahl, S. J., Barber, M. D., Richter, H. E., Visco, A. G., Sung, V. W., Shepherd, J. P., Rogers, R. G., Jakus-Waldman, S., Mazloomdoost, D., & NICHD Pelvic Floor Disorders Network (2019). Responsiveness and minimally important difference of sf-6d and eq-5d utility scores for the treatment of pelvic organ prolapse. American Journal of Obstetrics and Gynecology, (3), Article ARTN 265.e1-e11. https://doi.org/10.1016/j.ajog.2018.11.1094
BACKGROUND: Utility preference scores are standardized generic health related quality of life (HRQOL) measures that quantify disease severity and burden and summarize morbidity on a scale from 0 (death) to 1 (optimum health). Utility scores are widely used to measure HRQOL and in cost-effectiveness research.
OBJECTIVE: To determine the responsiveness, validity properties and minimal important difference (MID) of utility scores, as measured by the Short Form 6D (SF-6D) and EuroQol (EQ-5D), in women undergoing surgery for pelvic organ prolapse (POP).
STUDY DESIGN: This study combined data from four large U.S. multicenter surgical trials enrolling 1,321 women with pelvic organ prolapse. We collected condition-specific quality of life data using the Pelvic Floor Distress Inventory (PFDI) and Pelvic Floor Impact Questionnaire (PFIQ). A subset of women completed the SF6D; women in two trials also completed the EQ5D. Mean utility scores were compared from baseline to 12 months after surgery. Responsiveness was assessed using effect size (ES) and standardized response mean (SRM). Validity properties were assessed by 1) comparing changes in utility scores at 12 months between surgical successes and failures as defined in each study and 2) correlating changes in utility scores with changes in the PFDI and PFIQ. MID was estimated using both anchor-based (SF-36 general health global rating scale "somewhat better" vs. "no change") and distribution-based methods.
RESULTS: The mean SF-6D score improved 0.050, from 0.705 +/- 0.126 at baseline to 0.761 +/- 0.131 at 12 months, p<0.01. The mean EQ-5D score improved 0.060, from 0.810 +/- 0.15 at baseline to 0.868 +/- 0.15 at 12 months, p<0.01. ES (0.13-0.61) and SRM (0.13-0.57) were in the small to moderate range, demonstrating responsiveness of the SF-6D and EQ-5D similar to other conditions. SF-6D and EQ-5D scores improved more for prolapse reconstructive surgical successes than failures. The SF-6D and EQ-5D scores correlated with each other (r=0.41; n=645) and with condition-specific instruments. Correlations with the PFDI and PFIQ and their prolapse subscales were in the low to moderate range (r=0.09-0.38), similar to other studies. Using the anchor-based method, the MID was 0.026 for SF-6D and 0.025 for EQ-5D, within the range of MIDs reported in other populations and for other conditions. These findings were supported by distribution-based estimates.
CONCLUSION: The SF-6D and EQ-5D have good validity properties and are responsive preference-based utility and general HRQOL measures for women undergoing surgical treatment for prolapse. The MIDs for SF-6D and EQ-5D are similar and within the range found for other medical conditions.
